Pulmonary
Hypertension -
A Patient's Survival Guide The premiere information
resource for people living and dealing with PH
It hit delays
at the printer, but the THIRD edition IS en route cross country
to the PHA offices... order your copy now to have it shipped
as soon as our supply arrives!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked
to many other patients, doctors, and researchers while writing
the Survival Guide. Dr. Ronald J. Oudiz and a team of physicians
with a deep knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials; in-depth discussion of PH
secondary to other diseases or conditions; a new
chapter on what to eat if you have PH; and
much, much more!Click
to get info on the guide and pre-order yourself a copy
MADISON TOWNSHIP -- He has his father's lanky frame, his mother's
large hazel eyes and the sweet cheerfulness of a happy 7-year-old.
No one knows where Jared Fracker, of Madison Township, got his
rare, usually disabling or fatal disease.
It has a dauntingly cumbersome name, primary pulmonary hypertension,
a progressive disease of unknown cause that results in the narrowing
of the blood vessels in the lungs, causing high blood pressure
and eventually leading to heart failure, according to the American
Lung Association.
CoTherix,
Inc. Announces Priority Review Designation by the FDA for Ventavis NDA
SOUTH SAN FRANCISCO, Calif., Sept. 8 /PRNewswire/ -- CoTherix, Inc.
today announced that its New Drug Application (NDA) for Ventavis(R) (iloprost)
Inhalation Solution has been accepted for review by the U.S. Food and
Drug Administration and has been granted priority review designation.
The priority review designation establishes a target action date of December
31, 2004, for the Ventavis NDA. Additionally, CoTherix's request for
orphan drug designation has been granted for the use of Ventavis to treat
pulmonary arterial hypertension.
Thelin(TM)
May Offer Alternative for PAH Patients Who Have Failed on Bosentan,
According to Data Presented at European Respiratory Society Congress
HOUSTON, Sept. 8 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals
(Nasdaq: ENCY) today announced the presentation of new clinical data
on
Thelin(TM) (sitaxsentan) in pulmonary arterial hypertension (PAH), at
the European Respiratory Society (ERS) 14th Annual Congress (September
4-8, 2004) in Scotland. Data from this single center experience suggests
that Thelin may offer an alternative for PAH patients whose conditions
are worsening on bosentan. Two other abstracts were presented at the
ERS meeting on Thelin.
Data from this first study was presented by clinical investigator
Adaani Frost, M.D., Baylor College of Medicine, Houston, Texas.
Entitled, "Sitaxsentan
Sodium for the Treatment of Pulmonary Arterial Hypertension in Patients Failing
Bosentan: Preliminary Single Center Data," the trial showed that 10 out
of 11 PAH patients who had failed on bosentan due to clinical deterioration
or liver toxicities improved or stabilized when given Thelin oral therapy.
All 10 patients are continuing on Thelin today, some as long as 10 months.
LONDON (Reuters) - Pfizer Inc will give results of a clinical trial
next month that could confirm its best-selling anti-impotence drug Viagra
as a competitor to Actelion's Tracleer in treating a deadly form of hypertension.
A Pfizer spokeswoman confirmed on Friday that results of a study looking
at Viagra's use in treating pulmonary arterial hypertension would be
presented at the annual meeting of the American College of Chest Physicians
in Seattle on October 27.
Investors in Swiss biotech firm Actelion have been anxiously awaiting
the data, which is widely expected to confirm that Viagra is an effective
medicine in controlling the crippling heart and lung disease.
Safety and Hemodynamic Effects of Pulmonary Angiography in Patients with Pulmonary Hypertension: 10-Year Single-Center Experience
...retrospective review was performed for all patients who underwent pulmonary
angiography over a 10-year period at a single institution. Patients with
moderate pulmonary hypertension (pulmonary artery pressure, 30-59 mm Hg)
and severe pulmonary hypertension (pulmonary artery pressure, 60 mm Hg)
served as the study population. Demographic data, clinical indication, pre-
and postcontrast pulmonary artery pressure measurements, type of pulmonary
hypertension, contrast agent volume, complications, and American Society
of Anesthesiologists (ASA) classification were recorded for all patients
and compared.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
